These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1072 related articles for article (PubMed ID: 12912945)

  • 41. Aberrant hypermethylation of RASSF1A promoter in ovarian borderline tumors and carcinomas.
    Choi YL; Kang SY; Shin YK; Choi JS; Kim SH; Lee SJ; Bae DS; Ahn G
    Virchows Arch; 2006 Mar; 448(3):331-6. PubMed ID: 16315018
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serine/threonine kinases 31(STK31) may be a novel cellular target gene for the HPV16 oncogene E7 with potential as a DNA hypomethylation biomarker in cervical cancer.
    Yin FF; Wang N; Bi XN; Yu X; Xu XH; Wang YL; Zhao CQ; Luo B; Wang YK
    Virol J; 2016 Apr; 13():60. PubMed ID: 27044426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
    Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia.
    Steenbergen RD; Kramer D; Braakhuis BJ; Stern PL; Verheijen RH; Meijer CJ; Snijders PJ
    J Natl Cancer Inst; 2004 Feb; 96(4):294-305. PubMed ID: 14970278
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Promoter hypermethylation of the tumor-suppressor genes RASSF1A, GSTP1 and CDH1 in endometrial cancer.
    Fiolka R; Zubor P; Janusicova V; Visnovsky J; Mendelova A; Kajo K; Lasabova Z; Plank L; Danko J
    Oncol Rep; 2013 Dec; 30(6):2878-86. PubMed ID: 24068440
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
    Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
    Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
    López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
    Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic significance of DAPK and RASSF1A promoter hypermethylation in non-small cell lung cancer (NSCLC).
    Niklinska W; Naumnik W; Sulewska A; Kozłowski M; Pankiewicz W; Milewski R
    Folia Histochem Cytobiol; 2009; 47(2):275-80. PubMed ID: 19926549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
    Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
    Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Methylation of RASSF1A gene promoter and the correlation with DNMT1 expression that may contribute to esophageal squamous cell carcinoma.
    Du Z; Ma K; Sun X; Li A; Wang H; Zhang L; Lin F; Feng X; Song J
    World J Surg Oncol; 2015 Apr; 13():141. PubMed ID: 25886188
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Promoter hypermethylation profile of kidney cancer.
    Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
    Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Frequent hypermethylation of promoter region of RASSF1A in tumor tissues and voided urine of urinary bladder cancer patients.
    Chan MW; Chan LW; Tang NL; Lo KW; Tong JH; Chan AW; Cheung HY; Wong WS; Chan PS; Lai FM; To KF
    Int J Cancer; 2003 May; 104(5):611-6. PubMed ID: 12594816
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
    Tokinaga K; Okuda H; Nomura A; Ashida S; Furihata M; Shuin T
    Oncol Rep; 2004 Oct; 12(4):805-10. PubMed ID: 15375503
    [TBL] [Abstract][Full Text] [Related]  

  • 54. RASSF1A promoter methylation was associated with the development, progression and metastasis of cervical carcinoma: a meta-analysis with trial sequential analysis.
    Zheng F; Yu H
    Arch Gynecol Obstet; 2018 Feb; 297(2):467-477. PubMed ID: 29288321
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis.
    Dreijerink K; Braga E; Kuzmin I; Geil L; Duh FM; Angeloni D; Zbar B; Lerman MI; Stanbridge EJ; Minna JD; Protopopov A; Li J; Kashuba V; Klein G; Zabarovsky ER
    Proc Natl Acad Sci U S A; 2001 Jun; 98(13):7504-9. PubMed ID: 11390984
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence.
    Marsit CJ; Kim DH; Liu M; Hinds PW; Wiencke JK; Nelson HH; Kelsey KT
    Int J Cancer; 2005 Mar; 114(2):219-23. PubMed ID: 15540210
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix.
    Blanco-Luquin I; Guarch R; Ojer A; Pérez-Janices N; Martín-Sánchez E; Maria-Ruiz S; Monreal-Santesteban I; Blanco-Fernandez L; Pernaut-Leza E; Escors D; Guerrero-Setas D
    Pathol Int; 2015 Sep; 65(9):476-85. PubMed ID: 26222671
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inactivation of RASSF1A tumor suppressor gene by aberrant promoter hypermethylation in human pituitary adenomas.
    Qian ZR; Sano T; Yoshimoto K; Yamada S; Ishizuka A; Mizusawa N; Horiguchi H; Hirokawa M; Asa SL
    Lab Invest; 2005 Apr; 85(4):464-73. PubMed ID: 15711568
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quantitative analysis of mRNA expression levels and DNA methylation profiles of three neighboring genes: FUS1, NPRL2/G21 and RASSF1A in non-small cell lung cancer patients.
    Pastuszak-Lewandoska D; Kordiak J; Migdalska-Sęk M; Czarnecka KH; Antczak A; Górski P; Nawrot E; Kiszałkiewicz JM; Domańska D; Brzeziańska-Lasota E
    Respir Res; 2015 Jun; 16(1):76. PubMed ID: 26112163
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas.
    Vinothkumar V; Arunkumar G; Revathidevi S; Arun K; Manikandan M; Rao AK; Rajkumar KS; Ajay C; Rajaraman R; Ramani R; Murugan AK; Munirajan AK
    Tumour Biol; 2016 Jun; 37(6):7907-13. PubMed ID: 26700669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 54.